Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Low Eosinophil Patients Have 39% Reduction, Supporting Broad Label
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
